Epoke purchases additional shares of HLB Innovation and HLB Therapeutics
Major clinical results including RGN-259·SynKIR-310 scheduled to be released within the year
Jin Yang-gon, chairman of HLB (028300) Group, secured additional shares of HLB Group affiliates through a private corporation following his personal name.
HLB Group announced on the 2nd that Epoke, a financial investment company in which Chairman Jin holds a 99% stake, recently purchased additional shares of HLB Innovation and HLB Therapeutics on the market.
Epoke purchased 218,718 shares of HLB Innovation stock four times from the 23rd of last month to the 1st of this month. Accordingly, the number of shares held increased from 75,694 to 294,412.
Additional shares of HLB Therapeutics were also secured. He purchased 130,584 shares on the market three times on the 23rd and 30th of last month and on the 1st of this month, increasing his holdings from 41,688 to 172,272.
The two companies are scheduled to disclose clinical results of their major new drug pipelines within the year.
HLB Therapeutics is conducting a global phase 3 clinical trial (SEER-2) for the neurotrophic keratitis (NK) treatment candidate ‘RGN-259’ and plans to announce topline results in November.
Verismo Therapeutics, an American subsidiary of HLB Innovation, is developing ‘SynKIR-110’, a CAR-T treatment for solid tumors, and ‘SynKIR-310’, a CAR-T treatment for blood cancer. SynKIR-310 is being clinically tested on patients with relapsed or refractory B-cell lymphoma, and the interim results of the phase 1 clinical trial are scheduled to be released at the American Society of Hematology (ASH) in December.
Chairman Jin has been purchasing stocks of group affiliates, including HLB Innovation, HLB Panazine, HLB Therapeutics, HLB Genex, HLB BioStep, and HLB Pep, in his personal name this year. According to the company, about 1.22 million shares were purchased on the market a total of 62 times this year.
An HLB Group official said, “Chairman Jin Yang-gon has continued to purchase stocks of group affiliates in his personal name this year, and this time he secured additional shares in major affiliates through a private corporation. This shows trust in not only the ongoing new drug business, but also the follow-up pipeline and the mid- to long-term growth potential of each affiliate.”
